As Novo Nordisk campaigns against counterfeit versions of Ozempic, its Type 2 diabetes drug popularly used for weight loss, one analysis predicts the therapy will log $16.1 billion in sales in 2024, making it the second top-selling drug.
Category: GLP-1s
Transplants get a boost thanks to weight loss drugs
Hospital transplant departments have strict cutoffs for patients with higher body mass indexes because of the increased risk of complications, but GLP-1s such as Ozempic and Wegovy are helping more patients be eligible for surgery.
Novo Nordisk working with global authorities to take down fake Ozempic: Reuters
Counterfeit versions of Novo Nordisk’s Ozempic are becoming more of a concern, both for the company and to global authorities. Lars Fruergaard Jørgensen, the Danish drugmaker’s CEO, told Reuter’s the company is currently working alongside authorities i…
